Interested in the current clinical landscape on COPD? Read on for an overview on the latest clinical research based on data analysis from TA Scan.
Social impact
Chronic Obstructive Pulmonary Disease (COPD) is now one of the top three causes of death worldwide and 80% of these deaths occur in low- and middle-income countries. More than 3 million people died of COPD, accounting for 6% of all deaths globally. (1) (2)
Some of the most important risk factors associated with COPD are tobacco smoke inhalation, exposure to environmental pollutants, chemical gases, fumes, and dust particles.
Global clinical landscape
4,533 trials and 2,234 sponsors have brought together 1,562 global investigators. The most active regions (in number of trials) are Europe (1,151), North America (451), and China (128). With 542 currently ongoing trials, of which 426 started during the COVID-19 pandemic, it is clear that this disease area has not lost any awareness.
Access TA Scan to quickly identify 1,562 investigators, their collaborators, and 2,863 clinical study sites associated with these ongoing trials. Most of these trials (85%) are academically sponsored, and for the 15% remaining, the top commercial sponsors are GSK (343 trials), Boehringer Ingelheim (276 trials), and AstraZeneca (213 trials).
Global distribution of investigators for ongoing COPD trials
Pharmacological therapies for COPD
Chronic Obstructive Pulmonary Disease has 218 drugs (registered globally) in TA Scan. There’s currently no cure for COPD, the available drugs are used to maintain the progression of the disease. The pie chart below shows the top 10 drugs ranked by number of ongoing trials in COPD, going from 117 trials (Formoterol) to 59 trials (Fluticasone).
Top 10 COPD drugs: trial count
Two “new drugs” are in process for treating COPD and are in Phase 1-4: Umifenovir [NCT03851991] and gsk3923868 [NCT04585009]. In TA Scan you can see Gantt charts like the one below to get a time frame perspective for trials. You can hover over this chart to get key trial information, or click on the trial IDs to obtain more information through the trial drill-down.
Trial timeline for “new drugs” in COPD
Stay informed with TA Scan
Are you interested in knowing more about Chronic Obstructive Pulmonary Disease or any of our other 525 therapeutic areas? Our clinical intelligence solution TA Scan allows you to extract relevant information and perform powerful analytics to get faster, data-driven insights for your business objectives ranging from Clinical Operations to Medical Affairs.
If you have any questions regarding TA Scan or other solutions in Data Science suite, please contact us or schedule a demo.